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LONG-TERM ASSESSMENT OF NO EVIDENCE
OF DISEASE ACTIVITY IN RELAPSING-
REMITTING MS
The advent of new effective therapies for relapsing-
remitting (RR) multiple sclerosis (MS) has increased
the expectations for disease control. This has made
it crucial to use measures able to accurately evaluate
the impact of therapeutic intervention, shifting the
treatment paradigm of MS from partial response to
remission.1
Measures combining both clinical and MRI activity
are increasingly used in MS to assess patients’ disease
status and capture the beneficial effect of disease-
modifying therapies (DMTs). In particular, the concept
of no evidence of disease activity (NEDA) has become an
appealing new outcome measure in clinical trials and a
conceivable goal for the treatment of MS.1,2 NEDA is
currently defined by incorporating absence of activity due
to new/enlargingMRI lesions and clinical relapses as well
as absence of sustained disability progression as measured
by the Expanded Disability Status Scale (EDSS). Since
this definition is heavily weighted towards focal inflam-
matory disease activity, the addition of measures of brain
volume loss (BVL) to the NEDA definition (NEDA-4)
has been proposed recently for a more comprehensive
assessment of both disease activity and worsening.3
Most of the current NEDA assessments in patients
with MS have been done as exploratory analyses of
clinical trials2–4 and therefore have a limited time
frame (e.g., 2–3 years). Recently, a longer study from
a real-world cohort of patients with RRMS under
mixed drug therapies has been performed,5 showing
that NEDA can be found over 7 years in a minimal
proportion of patients with MS (7.9%). To provide
new insights into the long-term persistence of NE-
DA, we performed a study assessing NEDA and
NEDA-4 in a cohort of patients with RRMS with
10-year clinical and MRI follow-up.
Methods. Ninety-one patients with RRMS (mean6
SD age 34.2 6 8.4 years, disease duration 5.3 6 6
years, median EDSS 1.5, 71% female) were recruited
between January 2000 and May 2001 among those
who were referred to the MS Clinics of the Universities
of Siena and Florence, and the Hospital of Empoli,
Tuscany, Italy. During an average follow-up of 10.2
years (range 9.3–12.5), patients underwent yearly
clinical assessment, which included relapse recording
and EDSS scoring, and 2 identical brain MRI
examinations (at start and end of study). Brain MRIs
were acquired using the same 1.5T Philips Gyroscan
(Philips Medical Systems, Best, the Netherlands) and
an identical protocol consisting of a dual-echo, turbo
spin-echo sequence yielding proton density and T2-
weighted images for assessment of brain lesions and
T1-weighted images for measurement of BVL
(quantified using the SIENA method6). During the
follow-up, 83/91 patients were under treatment: 79
with injectable, first-line drugs (i.e., interferons or
glatiramer acetate) and 4 with immunosuppressants;
13 patients were unresponsive to first-line drugs and
were thus switched to second-line therapies. NEDA
was defined as absence of new/enlarging T2 lesions
on MRI, clinical relapses, and sustained EDSS
progression (defined as an EDSS increase of at least
1 point confirmed 6 months apart). NEDA-4 was also
assessed, keeping the annualized value of20.4% as the
cutoff for no evidence of BVL as previously described.7
The Ethics Committee of the Azienda Ospedaliera
Universitaria Senese approved this study.
Results. At follow-up, 19/91 patients with RRMS
were free from MRI activity (21%), 30/91 were free
from relapses (33%), and 50/91 were without
sustained EDSS progression (55%) ( F1figure). Also,
34/91 patients (37%) showed BVL below the
defined annualized value of 20.4%. There were no
clear differences in NEDA between treated and
untreated patients, likely due to the small sample
size of the latter group.
Discussion. NEDA can represent the benchmark in
the management of patients with MS, but a recent
study has shown difficulties in sustaining this target
in the long term even with treatment. The present
study extends previous work, providing compelling
evidence that NEDA, although it is known to occur
more in patients with treated vs untreated MS in the
short term,3 rarely persists after 10 years in a real-
world cohort of patients with RRMS. Interestingly,
NEDA is even more difficult to sustain when a
marker of diffuse brain tissue damage and potentially
of neurodegeneration, such as BVL, is included in the
definition (i.e., NEDA-4). In this respect, it needs to
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be stressed that, although most patients were under
treatment with DMTs, the study was started at a
time when only injectable DMTs were available, and
so it is likely that more patients could reach NEDA-4
with modern DMTs.3
Results of the study suggest that NEDA remains an
interesting outcome for clinical trials, but might not be
an easy goal in the clinical setting with current DMTs.
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Figure Detailed description of disease activity in the 3 main no evidence of disease activity (NEDA)
components in our patients with relapsing-remitting multiple sclerosis
Red, blue, and yellow circles represent, respectively, patients with evidence of newMRI lesions (MRI1), clinical relapses (REL1),
or sustained disability progression (Expanded Disability Status Scale [EDSS]1). Circles with mixed colors represent patients
with evidence of disease activity inmore than one outcomemeasure. The white circle represents the remaining NEDApatients.
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